Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.

AACR 2018

EORTC 2017

AACR 2017

EORTC 2016

EACR 2016

EORTC 2015

AACR 2015

AACR 2014

EORTC 2014